Cardiovascular Innovation Devices – Artificial Heart, Non-Invasive Radiotherapy, and ECMO

From fully magnetically levitated artificial hearts to the world's first non-invasive cardiac radiotherapy system, and from domestically produced ECMO to next-generation interventional devices — China is revolutionizing cardiovascular care.

I. Introduction: The Cardiovascular Innovation Boom

Cardiovascular disease remains the leading cause of death worldwide, and China bears a disproportionate burden — with over 330 million patients living with cardiovascular conditions. The demand for advanced cardiovascular devices has driven a wave of innovation in China, particularly in devices that were previously dominated by Western manufacturers.

This article reviews the most significant cardiovascular device breakthroughs in China in 2026, including the fully magnetically levitated artificial heart, the world's first non-invasive cardiac radiotherapy system, and the domestically produced ECMO system that has broken a two-decade import monopoly.

I. The Fully Magnetically Levitated Artificial Heart

China is now home to one of only two fully magnetically levitated artificial heart systems approved worldwide. This technology represents the pinnacle of ventricular assist device (VAD) engineering, offering patients with end-stage heart failure a bridge to transplant or destination therapy.

Technology Overview

The fully magnetically levitated artificial heart uses magnetic bearings to suspend the impeller in mid-air, eliminating mechanical contact and wear. Key advantages over earlier-generation VADs include:

• No mechanical bearings — eliminating a major source of device failure and thrombosis
• Reduced hemolysis — less damage to red blood cells compared to mechanical-bearing pumps
• Quieter operation — patients report significantly less noise and vibration
• Longer device lifespan — potentially exceeding 10 years of continuous operation

Clinical Experience

Multiple Chinese centers have now accumulated significant experience with the fully maglev artificial heart. In a series of cases presented at the 2026 Chinese Society of Cardiology annual meeting:

• 6-month survival exceeded 90% in patients receiving the device as bridge to transplantation
• Quality of life scores improved significantly, with patients able to return to normal activities
• Device-related complications were substantially lower than historical rates with earlier-generation VADs

II. Non-Invasive Cardiac Radiotherapy Robot: A Paradigm Shift in Arrhythmia Treatment

In 2026, China unveiled the world's first X-band cardiac arrhythmia non-invasive radiotherapy robot system — a device that combines radiation oncology precision with cardiac electrophysiology mapping to treat arrhythmias without surgery or catheter ablation.

Technology Overview

The system integrates:

• High-precision X-band linear accelerator — delivering focused radiation to arrhythmogenic foci
• Real-time cardiac electrophysiological mapping — identifying the precise location of arrhythmia origin
• 4D respiratory gating — tracking cardiac and respiratory motion to target the moving heart with sub-millimeter accuracy

Clinical Significance

This is the first device to combine radiation therapy and cardiac electrophysiology for the treatment of cardiac arrhythmias. The system fills a global technological gap in cardiac non-invasive radiotherapy treatment.

For patients with ventricular tachycardia or atrial fibrillation who are not candidates for catheter ablation — due to prior failed procedures, comorbidities, or difficult-to-access arrhythmia foci — this system offers a non-invasive alternative that can be performed in a single outpatient session.

III. ECMO: Breaking the Import Monopoly

Extracorporeal membrane oxygenation (ECMO) — a life-support system that provides cardiac and respiratory support to patients with severe heart or lung failure — was long dominated by a few Western manufacturers. That began to change in 2023, when Hannuo Medical's Lifemotion® ECMO system received domestic marketing authorization, ending a two-decade import monopoly.

Lifemotion® ECMO System

By the end of 2025, the Lifemotion® ECMO system had been installed in approximately 250 units, covering nearly 200 hospitals nationwide, with over 78% coverage of top-tier Class A tertiary hospitals including Beijing Anzhen Hospital, 301 Hospital, and West China Hospital.

Global Expansion

In early 2025, Lifemotion® received EU CE MDR certification, becoming the first domestically produced ECMO system to enter the international market. In March 2026, its independently developed single-use membrane oxygenator obtained U.S. FDA market access.

Market Projections

China's ECMO system market reached 1.002 billion yuan (approximately $138 million) in 2025. According to Frost & Sullivan forecasts, the market is expected to grow from 960 million yuan in 2024 to 4.38 billion yuan by 2030, with a compound annual growth rate of 28.7%, and is projected to exceed 10 billion yuan ($1.4 billion) by 2035.

In June 2026, Beijing Aerospace Changfeng's ECMO system ACM9000 was accepted into China's priority review green channel for innovative medical devices.

IV. Interventional Left Ventricular Assist Device: World-First Motor-Separated Design

In 2026, China approved the world's first motor-separated interventional left ventricular assist device. Unlike traditional LVADs that house the motor within the pump itself, this system separates the motor from the pump, allowing for:

• Smaller pump diameter — enabling percutaneous implantation via catheter
• Reduced heat generation — the motor, the main source of heat, is positioned outside the body
• Longer pump life — reduced wear and tear

The system provides temporary hemodynamic support during high-risk percutaneous coronary interventions or as a bridge to recovery in patients with cardiogenic shock.

V. Other Cardiovascular Device Approvals in 2026

In 2026, China approved a wide range of cardiovascular devices through the innovative device pathway, including:

• Cardiac pulse field ablation system — a novel energy modality for atrial fibrillation ablation
• Transcatheter tricuspid valve clamping system — addressing a historically underserved patient population with tricuspid regurgitation
• Pulmonary artery denervation system — for the treatment of pulmonary hypertension

VI. What This Means for International Patients

For international patients considering cardiovascular treatment in China:

• Access to world-first devices — including the non-invasive cardiac radiotherapy robot and motor-separated LVAD
• Advanced ECMO support — with domestically produced systems widely available at top-tier hospitals
• Cost advantage — cardiovascular device procedures in China are significantly more affordable than in the U.S. or Europe
• High procedural volume — Chinese centers perform among the highest volumes of cardiovascular interventions globally

Conclusion

China's cardiovascular device sector has undergone a remarkable transformation, with domestically produced innovations now matching or exceeding international standards. From fully maglev artificial hearts to non-invasive cardiac radiotherapy, Chinese devices are expanding treatment options and improving outcomes for patients worldwide.